REBYOTA^® Support & Resources

You may qualify for financial assistance through Ferring Pharmaceuticals.

REBYOTA Co-pay Program

Commercially insured, eligible PATIENTS MAY PAY AS LITTLE AS $100^a for each REBYOTA prescription.

^aAvailable only for patients who meet eligibility requirements. The program does not cover the cost of administration, office visits, or any associated costs. Terms and conditions apply. Offer expires 12/31/25.

- For commercially insured individuals whose insurance plans cover REBYOTA
- Must be 18 years of age or older
- Offer valid only in the US
- Must have been administered REBYOTA for an FDA approved indication

See additional terms and conditions below.

To enroll in the REBYOTA Co-pay Program, please speak with your doctor.
For additional assistance, call 1-877-REBYOTA

This offer is not contingent on any past, present or future purchase, including refills. This REBYOTA Co-pay Program offer is good for use only upon the administration of REBYOTA (“Product”) for an FDA approved indication in the US. The value of this program is exclusively for the benefit of patients and is intended to be credited towards patient out-of-pocket obligations for REBYOTA including applicable co-payments, coinsurance, and deductibles. Ferring will provide coverage maximum cap of up to $5,000 per dose with a maximum benefit of $10,000 per patient per calendar year. The value of this offer may not exceed the amount of the patient’s out-of-pocket costs for the Product. Documentation including Explanation of Benefits (EOB) will be required. The REBYOTA Co-pay Program is not health insurance. Offer is invalid for all transactions and claims submitted more than 180 days following the date of service. The REBYOTA Co-pay Program is not valid for Product reimbursed in whole or in part by Medicare, Medicaid, or a Medicare Part D plan, TRICARE, US Department of Veteran Affairs, US Department of Defense, the Commonwealth of Puerto Rico, government health insurance plan, or any other federal or state-funded healthcare benefit program. The REBYOTA Co-pay Program is void where prohibited by law, taxed, or restricted, as in the States of California and Massachusetts. The REBYOTA Co-pay Program is not transferable and is limited to one program benefit per patient. No substitutions are permitted. The REBYOTA Co-pay Program benefit cannot be combined with any other co-pay program, free trial, discount, prescription savings card, or other offer. Patients, pharmacists, and prescribers cannot seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this offer. Ferring Pharmaceuticals reserves the right to rescind, revoke, or amend this offer without notice. Offer expires 12/31/25.

REBYOTA Patient Assistance Program^a

You may be eligible to receive REBYOTA at no cost if you qualify for the Ferring REBYOTA Patient Assistance Program (PAP). Simply ask your doctor’s office to enroll on your behalf through REBYOTA Connect.

- You must be prescribed REBYOTA for an FDA approved indication
- You reside in the US
- You are being treated by a US-licensed healthcare provider
- Income restrictions apply

See additional terms and conditions below.

To learn more about the REBYOTA Patient Assistance Program
and to see if you qualify, please speak with your doctor.

The REBYOTA Patient Assistance Program is only available for qualified patients enrolled in REBYOTA Connect.

Participation in the PAP is free. Ferring does not collect any fees from people seeking assistance through PAP.

Assistance is provided in the form of free product shipped to site of administration or reimbursement for the invoiced cost of the product if processed after product has been administered. If assistance is in the form of free product, REBYOTA must be secured at the site of administration until the qualified PAP patient’s treatment date, and the medicine must be provided only to the eligible patient at no charge of any kind for the product. If product administration occurs and patient was qualified for PAP, reimbursement for the invoiced cost of the product can occur for Healthcare Providers or Specialty Pharmacies after they have provided supporting documentation for the product cost only in addition to a completed Reimbursement Request form. The REBYOTA PAP only covers the cost of the product and not administration or other services.

Any medications supplied by Ferring as a result of enrollment in the PAP are for the use of the named patient only and will not be sold, traded, bartered, transferred, returned for credit, or submitted to any third party (such as Medicare, Medicaid, or other benefit provider) for reimbursement.

If REBYOTA is no longer medically necessary for a qualified patient’s treatment or if the patient’s insurance or financial status changes, this must be reported to REBYOTA Connect.

If patient authorization is signed, electronic verification of a patient’s financial status is available to help determine eligibility,

PAP beneficiaries with government insurance are eligible to obtain medication through the end of the calendar year. PAP beneficiaries with commercial insurance are eligible to obtain medication for up to 12 months.

Healthcare Providers may not submit claims or payment from this medication through an insurance plan of any kind. Patients may not seek true out-of-pocket (TrOOP) or other insurance credit for medication provided through the PAP.

If applicable, PAP recipients will have their health plans receive written notification.

Ferring may change or cancel the PAP at any time and Ferring reserves the right to terminate a patient’s enrollment in the PAP at any time.

If you were screened for additional financial assistance offerings through the REBYOTA Connect Program and were informed you do not qualify, please click here to file an appeal.

Patient Testimonials

See how REBYOTA has helped people keep recurrent C. diff infection from coming back. These are some of their inspiring stories.

Melissa’s story

Had REBYOTA been available sooner, I would have asked for it.

– Melissa, Clinical Study Patient

Most common side effects may include stomach pain,  diarrhea, bloating, gas, and nausea.¹

Individual results may vary.

For more information, please talk to your doctor and see full Prescribing Information. Melissa was compensated for her time.

Melissa’s Story: REBYOTA Patient Testimonial

Freda’s story

I just knew that if I had C. diff again,  I wasn’t going to survive. But my C. diff didn’t  come back after I had REBYOTA.

– Freda, Clinical Study Patient

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.¹

Individual results may vary.

For more information, please talk to your doctor and see full Prescribing Information. Freda was compensated for her time.

Freda’s Story: REBYOTA Patient Testimonial

Patricia’s story

For me, it was one dose and one visit, and that was it.

– Patricia, Clinical Study Patient

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.¹

Individual results may vary.

For more information, please talk to your doctor and see full Prescribing Information. Patricia was compensated for her time.

Patricia’s Story: REBYOTA Patient Testimonial

Heather’s story

It has been six months since REBYOTA. I have  not had another recurrence.

– Heather, Actual REBYOTA Patient

Most common side effects may include stomach pain, diarrhea, bloating, gas, and nausea.¹

Individual results may vary.

For more information, please talk to your doctor and see full Prescribing Information. Heather was compensated for her time.

Age 37 
Lives in Arizona with her husband  
Received REBYOTA^® March 2023

This is Heather’s personal story. She was compensated for her time. Individual results may vary. Please talk to your doctor for more information about REBYOTA. Please see full Important Safety Information.

As a newlywed, having C. diff was devastating. I dreamed of being this beautiful princess bride and everything was going to go great. The first year was supposed to be this big honeymoon period, and that was blown out of the water.

Initial Symptoms 
I was constantly running to the bathroom 3 to 4 times an hour. I was experiencing a lot of pain in my gut, which was new. The combination of nausea and pain was scary to me.

C. diff Diagnosis 
I had just recently been discharged from the hospital for another underlying condition. My C. diff doctor suspected that there might be more going on, so I was doing a lot of follow-ups.

C. diff Recurrence
I knew I had a recurrence of C. diff following bloodwork and other testing.

Getting REBYOTA
My C. diff doctor was the first person who brought up REBYOTA as an option. I went to the REBYOTA website to learn more about it and how it works.

My doctor’s office reached out to my insurance and REBYOTA was 100% covered by the government insurance I had at the time.

REBYOTA is available by prescription only. You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.

After Administration With REBYOTA
Once I finished receiving REBYOTA, my nurse left the room. I laid on my side for about 15 minutes, and then I was able to drive myself home afterwards.

I was so surprised because over the next few days I noticed a significant decrease in the number of times that I was rushing to the bathroom. The intensity seemed to subside significantly. As each day went on, I felt incrementally better, which hadn’t happened in so long.

Treatment times vary. Administered after completing a course of antibiotics for recurrent C. diff infection.

Life Since REBYOTA

It has been over six months since REBYOTA, and I have not had any recurrence of C. diff. When I leave the house now, I do not have any of the worries I used to.

Recently, I was so excited because my husband and I went to the Phoenix State Fair. We were there from opening at 10 AM to 10 at night. Six months ago, there was no way on earth I would have even conceived of going somewhere like that.

Individual results may vary. Patients should not take any oral antibiotic therapy for up to 8 weeks after administration of REBYOTA unless directed by their doctor.

Share your story

Have you received REBYOTA to keep your recurrent C. diff from coming back?

Share Your REBYOTA Story

Have you received REBYOTA and want to share your story with others?
Fill out the form below and we will contact you for more information.

First Name*(Required)

Last Name*(Required)

Email Address*(Required)

Phone Number (optional)

Preferred communication method*(Required)

Phone

Have you or a loved one been treated with REBYOTA?*(Required)

Yes

*Required field.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

By providing the information requested, I am confirming that I am a US resident, 18 years of age or older, and am giving Ferring permission to store and use the information that I have provided. I understand and agree that my information will be used by Ferring (or companies working on Ferring’s behalf) to contact me by telephone, email, or mail to provide me with information that may be of interest to me or to invite me to participate in research, educational, and marketing initiatives. I understand that my information will be treated as described in Ferring’s Privacy Notice, which provides details about my privacy rights. Also, I understand that I may opt out of the database at any time by making the request at Data Subject Form or by calling 1-888-FERRING, Monday through Friday, 8 _AM to 7 _PM ET to speak to a representative or leave a voicemail. This statement may be updated from time to time.

CAPTCHA

REBYOTA care resources

Resources to help you and others (including caregivers) who may be coping with recurrent C. diff infection.

Caregiver checklist

This caregiver checklist will help you take care of your loved ones with recurrent C. diff infection.

Submit

C. diff diary

Prepare for your doctor appointments with this printable C. diff diary. Track medical history, symptoms, questions, food and water intake, and more.

Submit

Patient brochure

Learn more about recurrent C. diff infection and how to keep it from coming back with REBYOTA.

Submit

Join an Online Research Panel

Have you suffered with C. diff or cared for someone who has? Or have you recently been administered REBYOTA? If so, please join an online research panel and help others living with C. diff.

Keep your recurrent C. diff infection from coming back

Learn how REBYOTA—in one dose, one visit—can keep your recurrent C. diff infection from coming back.

Keep exploring REBYOTA

About REBYOTA

Learn how one dose of REBYOTA can keep C. diff from coming back.

About REBYOTA

Getting REBYOTA

Learn how REBYOTA can be administered at your doctor’s office or in your home.

Getting REBYOTA

Sign up for more information

Receive additional information and resources to help you through your C. diff infection journey.

First Name*(Required)

Last Name*(Required)

Email Address*(Required)

Phone Number

What’s your experience with C. diff infection?*(Required)

What’s your experience with C. diff infection?*

I currently have a C. diff infection

I had a C. diff infection within the last year

I am a C. diff patient caregiver

I’m interested in learning more about C. diff

*Required field.

CAPTCHA

Please see Important Safety Information and full Prescribing Information

INDICATION

REBYOTA (fecal microbiota, live – jslm) is indicated for the prevention of recurrence of Clostridioides difficile (C. diff) infection in individuals 18 years of age and older, following antibiotic treatment for recurrent C. diff infection.
Limitation of Use
REBYOTA is not indicated for the treatment of C. diff infection.

Important Safety Information

You should not receive REBYOTA if you have a history of a severe allergic reaction (e.g., anaphylaxis) to REBYOTA or any of its components.
You should report to your doctor any infection you think you may have acquired after administration.
REBYOTA may contain food allergens.
Most common side effects may include stomach pain (8.9%), diarrhea (7.2%), bloating (3.9%), gas (3.3%), and nausea (3.3%).
REBYOTA has not been studied in patients below 18 years of age.
Clinical studies did not determine if adults 65 years of age and older responded differently than younger adults.

You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-1088.

Please click to see the full Prescribing Information.

You are leaving REBYOTA.com

The link you have selected will direct you to a site or resource outside of our website.
Thank you.

Okay

REBYOTA® Support & Resources

REBYOTA Co-pay Program

Commercially insured, eligible PATIENTS MAY PAY AS LITTLE AS $100a for each REBYOTA prescription.

REBYOTA Patient Assistance Programa

You may be eligible to receive REBYOTA at no cost if you qualify for the Ferring REBYOTA Patient Assistance Program (PAP). Simply ask your doctor’s office to enroll on your behalf through REBYOTA Connect.

Patient Testimonials

Melissa’s story

Freda’s story

Patricia’s story

Heather’s story

Share your story

Share Your REBYOTA Story

REBYOTA care resources

Caregiver checklist

C. diff diary

Patient brochure

Join an Online Research Panel

Keep your recurrent C. diff infection from coming back

Keep exploring REBYOTA

About REBYOTA

Getting REBYOTA

Sign up for more information

Please see Important Safety Information and full Prescribing Information

INDICATION

Important Safety Information

You are leaving REBYOTA.com

REBYOTA^® Support & Resources

Commercially insured, eligible PATIENTS MAY PAY AS LITTLE AS $100^a for each REBYOTA prescription.

REBYOTA Patient Assistance Program^a